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Objective: to develop a graft bearing an immunologically tolerated tissue-engineered venous valve (TE graft) that will be
incorporated into a native vessel, and restore normal valve function for the treatment of chronic venous insufficiency.
Methods: twenty-four TE grafts were grown using decellularised allogeneic ovine veins as donor matrix, which was
subsequently repopulated with the future recipient's myofibroblasts (MFB) and endothelial cells (EC). TE grafts were
implanted into the external jugular vein. Animals were sacrificed at 1, 6, and 12 weeks (n 4, each). Autografts served as
controls (1 week, n 4; 6 weeks, n 4). Specimen for histology and immunohistochemistry were taken.
Results: the matrix was successfully repopulated with MFB and EC (n 8). Patency on venography in the TE graft-group
was 44,
4
4, and
3
4 at 1, 6, and 12 weeks, and
4
4 (
4
4) in autografts at 1 (6) weeks, respectively. Except for 2 TE grafts after 12 weeks,
valves were competent (duplex ultrasound). Patent TE grafts were merely distinguishable from autografts with minor
inflammatory reactions. Reflux was caused by neo-intima formation related to the basis of the TE graft.
Conclusion: acellularisation and consecutive in vitro autogeneic re-seeding of valved venous conduits can lead to
immunologically acceptable, patent, and competent implants in sheep.
Key Words: Acellular matrix; Chronic venous insufficiency; Endothelial cell transplantation; Tissue-engineering; Vascular
graft; Vein valve reconstruction.
Introduction
Chronic venous insufficiency as post-thrombotic
sequelae represents a very common disorder with an
estimated incidence of 0.3±3% in Western Europe and
North America.1,2 Today, therapy remains symptom-
atic in nature, basically consisting of external support
of the legs by compression stockings. Very few
attempts of surgical repair have been made aiming at
restoration of valvular function in veins of the leg. In
most series, valves were repaired, or axillary vein
segments containing a venous valve were trans-
planted in an autologous fashion to replace the dis-
eased femoral or popliteal vein valve.3 Clinical
attempts of implantation using allogeneic or alloplas-
tic valvular structures are rare.4 Given the high inci-
dence of post-thrombotic syndromes combined with
insufficient treatment options, there is an urgent need
of long-term functioning implants restoring natural
flow conditions in the venous circulation of the leg.
This significant and clinically motivated demand has
been our stimulus to develop a new, tissue-engineered
(TE) venous blood vessel containing a venous valve.
Advantages of such TE vessels would include reduced
thrombogenicity and greater long-term durability,
based on its fabrication from viable, autologous cells
that can utilize the body's mechanisms for repair and
remodelling.5,6 The aim of this study was to compare
histology, immunology, patency, and function of endo-
thelial cell seeded decellularised allogeneic venous
valves with valve bearing venous autografts in vivo.
Materials and Methods
Laboratory animals and anaesthesia
Adult female sheep (40±50 kg) were obtained from
Tierzuchtanstalt Mariensee, Germany. All animals
received care in compliance with the `` Guide for the
Presented at the XVI Annual Meeting of the European Society of
Vascular Surgery, 26±29 September 2002, Lufti Kirdar ICEC,
Istanbul, Turkey. Awarded with the prize for the best experimental
paper.Please address all correspondence to: O. E. Teebken, Division of
Thoracic and Cardiovascular Surgery, OE 6210, Hannover Medical
School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
Eur J Vasc Endovasc Surg 25, 305±312 (2003)
doi:10.1053/ejvs.2002.1873, available online at http://www.sciencedirect.com on
1078±5884/03/040305 08 $35.00/0 # 2003 Elsevier Science Ltd. All rights reserved.
Care and Use of Laboratory Animals'' prepared by the
Institute of Laboratory Animal Resources, National
Research Council.7 Animals were anaesthetised with
1.5±4.5 mg/kg Fentanyl (Janssen, Neuss, Germany)
and 1.2±2.5 mg/kg Propofol (Braun, Melsungen,
Germany) after treatment with Carboprofen (Rimadryl,
Pfizer, Karlsruhe, Germany), intubated, and mechan-
ically ventilated (Servo Ventilator 900C, Siemens,
Sweden) with air and isoflurane (Forene, 1-
Chlor-2,2,2-trifluorethyl-difluormethylether, Abbott,
Wiesbaden, Germany).
Preparation of decellularised valved venous conduits
Valve bearing segments of the external jugular vein
(6 cm in length) were found competent by the manual
strip test, explanted, and immediately stored in phos-
phate buffered saline (PBS, Sigma, Germany) at 4 °C.8
The vessels were incubated in 20 ml 1 M sodium chlor-
ide solution under continuous shaking at 37 °C for 2 h.
This was followed by incubation with 20 mL 4%
sodium desoxycholate (Sigma) at 4 °C for 60 min.9
Decellularised vessels were washed for 18 h and sub-
sequently stored in PBS at 4 °C.
Cell isolation and expansion
Right external jugular veins were explanted and
stored in PBS at 4 °C. Endothelial cells (EC) were iso-
lated as described before10 and resuspended in 5 ml
EC culture medium (EC Basal Medium and Supple-
ment Kit for EC Growth Medium, Promocell,
Germany), containing 10% foetal calf serum (Life
Technologies, Germany), 100 IE/ml Penicillin, and
100 mg/ml Streptomycin (Biochrom, Germany). After-
wards the cells were placed in a 25 cm2 culture flask
(Corning Costar, Cambridge, MA, U.S.A.) precoated
with gelatine (gelatine type A, Sigma) with a resulting
density of 10 000 cells/cm2. Cells were incubated in a
5% CO2/95% air atmosphere and medium was
changed every second or third day. Just before mono-
layers were grown to confluency, the cells were
detached with 0.05% trypsin (Biochrom) and 0.02%
EDTA (Sigma) in PBS without Ca2 and Mg2 and
subcultivated in 175 cm2 flasks.
Following enzymatic extraction of EC the same
veins were prepared for isolation of myofibroblasts
(MFB). They were freed from adhering tissue, minced
into 1 mm2 fragments and placed into a culture flask.
After attachment of the fragments, culture medium
(Smooth Muscle Cell Basal Medium 2, Promocell)
was added. MFB grew to confluency within 5 days
and were passaged to 175 cm2 culture flasks. Media
was changed every third day. For seeding procedures,
EC and MFB from the second or third passage were
trypsinised, centrifuged and washed.
Bioreactor perfusion system and vessel culture
Decellularised venous specimens (n 24) with a length
of 6 cm were placed in a bioreactor (5% CO2/95% air/
37 °C), facilitating separate external (for MFB) and
luminal (EC) media perfusion. MFB (6 106 cells/cm2
vein) were given to the external medium circuit every
third day. For EC seeding of the grafts 1.2 106 EC
were injected into the luminal circuit at day 10. Flow
rates were adjusted at 7 ml/min. After 2 weeks cul-
tures were stopped for morphological analysis (n 8),
mechanical testing (n 4) or transplantation (n 12).
Implantation of tissue-engineered valved venous
conduits
The left external jugular vein was dissected over a
length of 8 cm following a skin incision medial to the
sternocleidomastoid muscle. A segment of 3±5 cm
length was removed after systemic heparinisation
(100 IE/kg). The same segment was either re-
implanted (autograft controls; n 8) or replaced by a
graft that was engineered from an allogeneic decellu-
larised matrix and re-seeded with autologous cells
in vitro (seeded allograft; n 12). Anastomoses were
performed with 7-0 polypropylene running sutures
(Prolene, Ethicon, Norderstedt, Germany). All animals
received antibiotics (cephalexinum monohydratum,
1200 mg/day) and analgetics (buprenorphin hydro-
chloride, 0.9 mg/day) for 4 days post-operatively.
Anticoagulants or antiplatelets were not administered
post-operatively.
Follow up, duplex ultrasound scan, and venography
Graft patency and function was examined by means of
duplex ultrasound scan (Sonos 5500, Hewlett Packard,
Palo Alto, CA, U.S.A.) using a 4 MHz probe period-
ically. Duration of venous valvular reflux was quanti-
fied by the method described by van Bemmelen and
colleagues.11 A cuff (Bosch und Sohn, Jungingen,
Germany) was placed around the neck approximately
4 cm distal to the venous valve. The pressure was
adjusted to 80 mmHg. The cuff was inflated for 3 s
and deflation occurred in less than 0.5 s. Velocity of
venous flow was recorded between the cuff and the
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transplanted valve. A reflux time of more than 1.5 s
was considered insufficient. All animals underwent
descending and ascending venography (Philips,
The Netherlands) with a non-ionic dye (Ultravist,
Schering, Berlin) immediately before they were sacri-
ficed either 1 or 6 weeks after implantation (four sheep
of each group). In addition, four animals in the seeded
allograft group survived for 12 weeks. Graft patency
was graded into `` patent'' and `` obstructed'', since
there were no stenoses of more than 20%.
Histology and immunohistochemistry
Valved venous conduits were explanted and histo-
logical sections were obtained. Samples for light
microscopy were stored in liquid nitrogen. Semi-thin
sections were stained with hematoxylin±eosin (HE),
van Gieson stain for evaluation of matrix components
especially elastic fibres, or von Kossa for detection of
calcifications. Endothelial cells were characterised by
immunohistochemical staining (avidin biotin peroxi-
dase technique) of frozen sections for the presence of
factor VIII-related antigen (polyclonal rabbit antihu-
man von Willebrand factor, DAKO, Hamburg,
Germany). Antibodies for vimentin (monoclonal
mouse antihuman vimentin, clone Vim 3B4) staining
to mark vascular cells (EC and MFB), and for desmin
(monoclonal mouse antihuman desmin, clone DE-
U-10) for detection of smooth muscle cells (SMC)
were purchased from DAKO. In addition, trans-
planted grafts were stained for CD11b, indicating acti-
vation of macrophages and procollagen type 1 (a
precursor of collagen type 1, indicating neo-synthesis
of extracellular matrix) with M38 protein. A biotiny-
lated horse anti rabbit IgG antibody (Vector, Burlin-
game, U.S.A.) and a horse antimouse antibody
(Vector) served as secondary antibodies. Negative
controls consisted of rabbit and mouse IgG (DAKO).
Streptavidine-peroxidase-conjugate was applied and
final staining was done with diaminobenzidine
(DAKO).
Statistical analysis
Continuous variables are expressed as mean plus or
minus one standard deviation (body weight) or
median and range. Differences between investigations
were evaluated by means of the non-parametric
Mann±Whittney test, if appropriate. A p5 0.05
was considered significant. SPSS 10.0 for Windows
was used.
Results
In vitro studies
Acellular matrix
The absence of cell nuclei and intracellular compo-
nents in the acellular matrix before re-seeding was
demonstrated by immunohistochemistry in 12 speci-
mens. Elastic fibres were well preserved (van Gieson
stain). Stains for von Willebrand factor, vimentin and
desmin were negative.
Morphology after culture in the bioreactor
Fourteen days after seeding with MFB and 3 days
after EC seeding, the vessels were removed from the
bioreactor. All 12 TE vessels showed normal macro-
scopic anatomy comparable to a native vein and were
mechanically stable. Burst strength ranged from 1550
to 2320 mmHg (median 2085 mmHg, n 4). A conflu-
ent monolayer of von Willebrand factor positive
EC was found on the luminal surface.12 A neo-
vascularisation was not found in the in vitro re-seeded
specimen, as shown by absence of von Willebrand
positive cells in the vessel wall. Compared to native
veins less interstitial cells were found in the extra-
cellular matrix and a number of cells were adherent
to the external surface (`` adventitia'') but did not
invade the extracellular matrix of the vessel wall. All
re-seeded vein segments stained positive for vimentin,
which characterized vascular cells. SMC, identified by
desmin, invaded the Tunica media and were arranged
in a longitudinal fashion. The van Gieson stain
showed that the majority of elastic fibres were located
in the region of the Tunica intima and that the adven-
titia contained mostly collagen fibres.
In vivo studies
Twenty external jugular vein segments were replaced
with 8 autografts and 12 TE grafts. All 20 animals had
an uneventful intra- and post-operative course. Body
weight increased from 42.3 3.5 kg (n 8) at the time
of graft implantation to 42.6 3.3 kg (n 8) after
1 week, and 48.0 4.6 kg (n 4) after 6 weeks in auto-
grafts, and from 41.9 3.9 kg (n 12) at the time of
graft implantation to 42.5 2.9 kg (n 12) after 1 week,
48.4 4.6 kg (n 8) after 6 weeks, and 54.5 3.7 kg
(n 4) in TE grafts after 12 weeks, respectively. There
were no statistically significant differences between
the two groups at the time of implantation
(p 0.849), after 1 week (p 0.930), and 6 weeks
(p 0.900).
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Ultrasound duplex scan and venography findings
At the time of implantation all grafts were patent and
competent as shown by duplex ultrasound scanning.
Graft patency in the tissue-engineered group
(ntotal 12) was 44, 44, and 34 at 1, 6, and 12 weeks,
respectively, and 44 in autografts (ntotal 8) at 1 and 6
weeks (n 4, each). All patent valves were competent
except for two valves in the tissue-engineered group
after 12 weeks. There were no differences in ultra-
sound duplex scan and venography findings.
Macroscopic findings
Directly after explantation, the perfusion test per-
formed with PBS given on top of the valve confirmed
patency and sufficient valve function in all grafts, but
three of the TE group. As shown by means of duplex
ultrasound and venography one vein graft was com-
pletely obstructed (12 weeks post-operatively) and
another two valves were incompetent (after 6 and
12 weeks, Tables 2 and 3). Longitudinal dissection
demonstrated smooth and glistening luminal surfaces
and movable valve leaflets, that were almost indistin-
guishable from the native vessel distal to the anasto-
moses, in all autografts and non-obstructed seeded
explants (Fig. 1). Small thrombi were seen macroscop-
ically at the commissures and sinuses of 24 TE
grafts after 1 week and 44 TE grafts after 6 weeks
(Fig. 2a,b).
Histology
Both, the HE and the van Gieson stain showed no
thrombi on the vessel surface or at the valve region
of autografts. Interstitial and luminal cells were dis-
tributed normally. In TE veins the van Gieson stain
showed small thrombotic formations containing ery-
throcytes at all valve commissures but not on the
vessel wall after 1 and 6 weeks. In the TE group,
valve leaflets were clearly detectable after 1 week,
whereas the leaflets were embedded in the extracellu-
lar matrix of a neo-intima in one case of four after 6
weeks (Figs 3 and 4) and one of four after 12 weeks (in
addition to the one obstructed graft). The Tunica
media and for some extent the tunica adventitia as
well of TE grafts contained elastic fibres (Fig. 4b).
The absence of calcification was proven with the von
Kossa stain in autografts and TE grafts.
Immunohistochemistry
EC: A confluent endothelial monolayer was demon-
strated on the vessel wall and leaflets of all autografts
and patent TE grafts after 1 and 6 weeks (Fig. 5a).
 
Segel leaflets 
Fig. 1. Venous autograft 6 weeks after implantation. Smooth and
glistening luminal surface. The valves are clearly visible and throm-
bosis is absent.
(a) (b)
l eaf l et s  
l eaf l et s  leaflets 
leaflets 
Fig. 2. Tissue-engineered valved venous conduits: (a) small thrombi at the sinuses after 1 week, (b) after 6 weeks.
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Fig. 3. Tissue engineered valved venous conduits, HE: (a) clearly visible leaflet 1 week after transplantation (40), (b) leaflet (S) embedded
in neo-intima (nI) 6 weeks after transplantation (200).
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Fig. 4. Van Gieson stain of tissue engineered valved venous conduits: (a) 1 week, (b, c) 6 weeks after implantation (40); vein wall (W), valve
leaflet (S), thrombi (T), neo-intima (nI).
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In addition, a vascularisation of the wall was visible,
comparable to native veins (Fig. 5a).
SMC: Typical longitudinally arranged desmin posi-
tive SMC were seen in the Tunica media of autografts
as well as TE grafts (Fig. 5b) after 1 and 6 weeks.
Furthermore SMC were demonstrated in the neo-
intima of TE grafts (Fig. 5c).
Leukocytes: CD11b positive leukocytes were not
demonstrated in the vessel wall or leaflets of auto-
grafts and TE grafts after 1 and 6 weeks (Fig. 5d).
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Fig. 5. Immunohistochemical characterization of tissue engineered valved venous conduits 6 weeks after implantation; (a) von Willebrand
factor (100), (b, c) desmin (100), (d) CD11b (200), (e) M38 protein, procollagen type 1 marker (100); vessel wall (W), valve leaflet (S),
neo-intima (nI).
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Procollagen type 1 synthesis: In contrast to native
veins, staining for procollagen type 1 was positive in
autografts and TE grafts after 1 and 6 weeks (Fig. 5e).
In regions with neo-intima formation, procollagen
synthesis was enhanced.
Discussion
The prevalence of valvular reflux in the deep and
superficial system correlates significantly with the
severity of clinical features.2 Transplantation of auto-
logous venous valves, e.g. derived from the axillary
vein, has been shown to be successful in correcting
reflux and improving calf pump function and is asso-
ciated with ulcer healing and relief of symptoms.13
Previous attempts for the treatment of chronic venous
insufficiency with natural tissue, that did not utilize
tissue-engineering techniques, including valve repair,
transplantation of autologous valves or cryopreserved
vein segments were encouraging.4,14,15 In this current
project valved venous conduits were grown in a bio-
reactor using a decellularised allogeneic ovine jugular
vein as donor matrix.
In contrast to prosthetic valves, the acellular vein
matrix can provide the complex physiological valve
structure as well as the mechanical stability (burst
strength4 2000 mmHg).16,17 Within 14 days of cul-
ture in the bioreactor, a rather short period of time
compared to TE vessels on polymer basis, a graft with
morphological and mechanical characteristics for suf-
ficient function in vivo was engineered.18 Distribution
of EC, SMC, and extracellular matrix fibres was com-
parable to native veins.
After implantation into the venous circuit, all auto-
grafts remained patent and sufficient and no signs of
thrombosis were found (Fig. 1). The duplex ultra-
sound and venography findings were confirmed by
macroscopic evaluation after explantation. These facts
demonstrate the safety and the suitability of our sheep
model and our diagnostic tools. In consequence,
implantation of venous segments into the external
jugular of sheep provides an appropriate option for
the in vivo evaluation of TE grafts, but it does not serve
as a model for the study of lower limb chronic venous
insufficiency since venous pressures are not elevated
during observation.14
TE venous valved conduits were successfully inte-
grated into the host with minor inflammatory reactions
(Fig. 2). The number of physiologically arranged SMC
and of newly synthesised and rebuilt extracellular mat-
rix increased with time after transplantation as demon-
strated by procollagen type 1 synthesis as well as the
presence of CD11b positive leukocytes (Figs 3±5).
All TE grafts remained patent and sufficient after
the first week. However, in contrast to autografts,
signs of thrombus formation occurred in the region
of the valve sinuses. In addition, we found one
complete occlusion after 12 weeks and two grafts
with fixed leaflets due to neo-intima formation. Since
histological examination of cultured vessels after 14
days showed a confluent endothelial monolayer (von
Willebrand factor) at the valve sinuses, it is postulated
that (1) EC in the region of the valve sinuses are not
adequately differentiated to exhibit full antithrom-
botic potential, and/or in consequence are (2) shared
off directly after implantation.10 The significance of a
confluent endothelial monolayer is underlined by the
fact that (non-seeded) acellular matrix grafts led to
thrombosis within the first 6 weeks after transplant-
ation (n 4, data not shown). Nonetheless it has to be
emphasised that the vessel wall of patent TE veins
resembles histology of native veins, is not subjected
to excessive tissue overgrowth and is free from calci-
fication after 1, 6, and 12 weeks.
Further studies must concentrate on adjusting cul-
ture conditions (pulsatile flow, medium), investigating
the functional status of EC, and in vitro testing of TE
graft thrombosis. Modifications of the post-operative
protocol including administration of heparin and anti-
platelets or the implementation of an arterio-venous
fistula to enhance flow may overcome the problem of
graft thrombosis.
In conclusion, the in vitro seeding (`` tissue-engineering'')
of decellularised valved venous conduits can lead
to immunologically acceptable, patent implants
with sufficient valve function in sheep. Improved
culture techniques may lead the way to transplan-
tation of tissue-engineered valves into the human
femoral vein and offer a new option for surgical
therapy of chronic venous insufficiency in selected
patients.
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